The largest patient online event in the world for headache returns this April 18-26.
The Migraine World Summit will bring together over 30 top experts, doctors and specialists to share new treatments, research and strategies for migraine and chronic headache. It is available to anyone with an internet connection.
What is headache? Common neurological disorders Headache disorders are among the most common neurological disorders. These include tension-type headache (TTH), migraine and chronic daily headache syndromes as well as the more rare disorders, cluster headache and trigeminal neuralgia. Underestimated and under-diagnosed Headache has been, and continues to be, underestimated in scope and scale and headache
Many of us may be guilty of describing a headache as a migraine, but there is a distinct difference. Migraine is not ‘just a headache’. It is a serious condition and can be frightening and utterly disabling. We all get stressed at work. And that’s not always a bad thing. Harnessed in the right way,
The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a
Move For Migraine Migraine remains an overlooked and misunderstood condition in many parts of Europe, including Belgium. The disease suffers from a lack of recognition and understanding, even from the first concerned parties (patients, caregivers, employers, etc.). This comes at a significant burden for the patients and at a high cost for society (1,650,000 working
INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least
For Industry. Cooperating in finding solutions for patients. WHAT CAN EMHA DO FOR THE INDUSTRY. Cooperating in finding solutions for patients. Working together is the only way to find effective and lasting solutions for migraine sufferers. By encouraging research, supporting projects and working to distribute reliable information, we can achieve a better quality of life
First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity
Poor medical care for people with migraine in Europe. EUROLIGHT STUDY—Migraine in Europe.Migraine is prevalent everywhere, and disabling. It is also neglected: consequently, it is underdiagnosed and undertreated. We analysed data from the Eurolight study on consultations and utilization of migraine-specific medications as indicators of adequacy of medical care in Europe. The study Migraine is
Listen to the song created by The German Cluster Headache association.
